VA-REGULA
Regula, a global developer of forensic devices and identity verification solutions, prepared a dedicated package of expert articles focused on document verification, tailored to meet the needs of carriers, border verification authorities, the hospitality industry, and businesses during the 2024 Olympics. These resources aim to address the unique challenges posed by the influx of international visitors, ensuring seamless and secure experiences for all.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724663488/en/
Effective Identity Verification for the Olympics 2024: how is it done? Regula's vision (Graphic: Regula)
France anticipates a significant boost in tourism and economic activity during the 2024 Olympics, with over 10 million visitors projected to generate an estimated €3 billion in revenue. This massive surge in visitors will not only increase the risk of fraud targeting consumers and businesses but also pose substantial challenges for security and access management. The influx of international guests underscores the critical need for advanced and comprehensive Identity Verification (IDV) systems.
Properly verifying and authorizing everyone at every stage of their Olympic journey is essential for maintaining security and ensuring smooth access to event venues and services.
1. Addressing Carrier Requirements for Advance Passenger Information
With recent EU regulations mandating the collection of advance passenger information, carriers face unprecedented challenges. Our topic, "How Carriers Can Tackle New Requirements for Gathering Advance Passenger Information," provides comprehensive insights and practical solutions to help carriers comply with these regulations efficiently. As the Olympics are hosted in France, this information is crucial for ensuring smooth travel experiences for millions of visitors.
2. Professional Border Verification Techniques
Border control is a critical component of international events. Our resources include:
- "How to Verify a Passport Like a Pro": A detailed guide on the best practices for passport verification.
- "How Regula Creates the Most Full and Detailed Document Reference System": An in-depth look at how Regula's advanced technology supports border control authorities with the most comprehensive document reference systems available. It contains templates of passports, ID cards, visas, banknotes, coins, driver’s licenses, and vehicle documents from all over the world.
- To gain a better understanding of the verification tools needed, from border controls to customer authorization by businesses, check the article “Regula ID Document Templates Database vs. Information Reference System”.
These topics are designed to empower border officials with the knowledge and tools needed to maintain security while facilitating the flow of visitors.
3. Transforming Travel & Hospitality with Data Entry Automation
In the hospitality sector, efficient check-ins are vital for a positive guest experience. At the same time, manual entry of ID details in hotels can often cause long lines, messes, and delays.
Our topic, "How Data Entry Automation Transforms Travel & Hospitality," highlights the latest innovations in reader technology and software. It provides examples of automated check-in processes and calls to action for hospitality businesses to leverage these advancements for a competitive edge.
4. Solving Business Challenges of Foreign Documents Verification
Businesses are facing an increase in the number of international customers, and the smart ones start adapting to the challenges of verifying foreign documents. Our article, "Foreign ID Document Verification for Businesses,” offers practical advice and solutions for businesses to navigate these complexities, ensuring they can confidently verify the identities of international customers.
To get access to all the expert articles in one place, visit the landing page “Securing the Olympics 2024”.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724663488/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press release
The Company generated net sales of $41.6 million for the quarter and $113.4 million year-to-dateIncome before income taxes of $5.1 million for the quarter and $13.2 million year-to-dateBacklog of $114.2 million at October 31, 2024, compared to $68.5 million at January 31, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom